Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2021-10-31
2025-01-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Physiotherapy aimed on the strengthening of diaphragm and lower esophageal region is effective in gastroesophageal reflux disease. Therefore we are expecting positive effect of physiotherapy in post POEM patients with reflux symptoms and the possible reduction of PPI drug usage need.
The aim of the study is to objectify the effect of physiotherapy, to describe in detail the used physiotherapeutic techniques and to develop practical guidelines for the treatment of patients after POEM with GERD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Systematic IPP VS Symptomatic IPP in GERD Prevention After POEM for Achalasia. . A Comparative Retrospective Analysis
NCT04740437
ARAT for Reflux Disease After Peroral Endoscopic Myotomy in Patients With Achalasia
NCT04065516
Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility
NCT03476265
Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
NCT00444236
Topical Pharyngeal Anesthesia in Sedated Esophagogastroduodenoscopy
NCT03070379
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A complication of POEM is the development of reflux, which occurs in up to 50% of patients (within 12 months), with the occurrence of severe esophagitis being rare. However, patients are treated with proton pump inhibitors (PPIs) after POEM, either daily or on-demand. As a result, patients after POEM are regularly monitored for the possible development of symptomatic or asymptomatic reflux, which (if left untreated) can lead to the development of complications, including Barrett's esophagus, a known precancerous lesion.
The main reason for reflux in patients after POEM is an insufficient function of the LES, which is formed not only by the smooth muscle of the esophagus, but also by the skeletal muscle- diaphragm, which remains intact during the POEM itself. Together, these two structures form a major component of antireflux barriers. Since the crural part of the diaphragm is a skeletal striated muscle, it is a trainable muscle.
The study will involve 30 patients after POEM with diagnosed reflux. Three months after POEM patients undergo follow-up examinations using high resolution manometry, 24hours pH test for reflux and gastroscopy. Based on the results of the examination in the 3rd month after the POEM, those who meet the inclusion criteria, will be offered to participate in this study. Patients will be asked to fill in the quality of life questionnaire of patients after POEM and the validated questionnaire for patients with reflux disease. Patients will be randomized in 2 groups (15 in both arms, ratio 1:1), one group will undergo 4 months of physiotherapy treatment using PPI on demand, second group will be a control group undergoing standard treatment of reflux symptoms with PPI on demand.
This study will evaluate the effect of standard treatment of post-POEM esophageal reflux compared to the effect of physiotherapy using dynamic neuromuscular stabilization in post-POEM patients with esophageal reflux.
There is currently no study looking at the effect of physiotherapy in post-POEM patients, we believe this could be a beneficial study.
If this study demonstrates that physiotherapy alleviates the symptoms of post-POEM reflux, it could be one of the official methods of treatment for this group of patients and thus significantly increase their quality of life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Physiotherapy
Patients will undergo physiotherapy and will be regularly examined by an assigned physician.
Initial physiotherapy will last 60minutes, other therapies will last 30minutes. Physiotherapy will aim on diaphragmatic breathing and dynamic neuromuscular stabilization exercises. In the 1st month, the patient attends physiotherapy once a week In the 2nd, 3rd and 4th month, the patient attends physiotherapy once every 14 days.
Symptomatic patients will take PPIs based on the recommendation of the treating physician who will recommend a dose of PPIs. Used PPIs will be Emanera 1x40mg (standard dose), 2x40mg (higher dose) or 1x40mg on demand.
During the follow-up period, patients may, in agreement with the attending physician, reduce the dose of PPIs (from twice a day to once a day, from once a day to an "on-demand" regime or discontinue them altogether).
The use of PPIs will be accurately documented.
Physiotherapy
After POEM, patient underwent physiotherapy consisting of diaphragmatic breathing and dynamic stabilization exercises and PPIs
Control group
Control group will undergo standard treatment of reflux with PPIs and will be regularly examined by an assigned physician.
Symptomatic patients will take PPIs based on the recommendation of the treating physician who will recommend a dose of PPIs. Used PPIs will be Emanera 1x40mg (standard dose), 2x40mg (higher dose) or 1x40mg on demand.
All patients with esophagitis LA A/B/C will be treated with IPP-Emanera 1x40mg for at least 6 weeks at the start of the study.
During the follow-up period, patients may, in agreement with the attending physician, reduce the dose of PPIs (from twice a day to once a day, from once a day to an "on-demand" regime or discontinue them altogether).
The use of PPIs will be accurately documented.
Control group
All patients will be treated with standard course of PPIs after POEM without physiotherapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Physiotherapy
After POEM, patient underwent physiotherapy consisting of diaphragmatic breathing and dynamic stabilization exercises and PPIs
Control group
All patients will be treated with standard course of PPIs after POEM without physiotherapy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. symptomatic post-POEM reflux and/or esophagitis LA A/B/C (grade by The Los Angeles Classification) present 3 months after POEM surgery
3. positive finding on esophageal 24hours pH Test 3 months after POEM surgery
4. signed informed consent
Exclusion Criteria
2. repeated POEM surgery
3. Esophagitis of LA grade D
4. asymptomatic pathologic reflux without signs of esophagitis 3 months post POEM surgery (patient is not indicated to use proton pump inhibitor "PPI" drugs)
5. previous gastric surgery
6. patients undergoing cancer treatment
7. pregnancy
8. known allergy or intolerance of proton pump inhibitor drugs
9. other circumstances preventing participation in the study
10. Inability to obtain informed consent
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute for Clinical and Experimental Medicine
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doc. (Ass. prof.) Jan Martinek, MD, PhD, AGAF
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kateřina Mádle
Role: PRINCIPAL_INVESTIGATOR
Charles University 2nd faculty of medicine, Prague, Czech Republic
Jan Martínek
Role: PRINCIPAL_INVESTIGATOR
Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Zuzana Vacková
Role: PRINCIPAL_INVESTIGATOR
Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Milan Martínek
Role: PRINCIPAL_INVESTIGATOR
Charles University Faculty of Physical Education and Sport
Lucie Zdrhová
Role: PRINCIPAL_INVESTIGATOR
Department of Internal Medicine, Pilsen, Czech Republic
Alena Kobesová
Role: PRINCIPAL_INVESTIGATOR
Charles University 2nd faculty of medicine, Prague, Czech Republic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute for Clinical and Experimental Medicine
Prague, Prague, Czechia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IClinicalEM4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.